

For Immediate Release

SENEXIS LAUNCHES NEW WEBSITE

Cambridge, UK, 26th April 2010 - Senexis Limited, a private drug development company announced today that it has launched its new website: www.senexis.com. The updated website provides information on the company's orally bioavailable compounds for the potential treatment of Alzheimer's disease.

Mark Treherne, Senexis' Chief Executive, commented: "we expect that our new website will help communicate recent advances in our pipeline and accelerate licensing discussions, as our small molecule compounds progress towards the clinic."

The number of people with Alzheimer's disease is expected to double over the next two decades. Currently, five million people in the US alone are affected by the disease.

CONTACTS Senexis Mark Treherne, Chief Executive +44 (0)7711 190 718

Tallphil Productions
Phil Ewels, Web Designer
+44 (0)7817 006 203

About Senexis

Senexis is a drug development company, dedicated to the discovery of effective treatments and diagnostics for major ageing-related diseases, such as Alzheimer's dementia. It is now widely believed that the misfolding and aggregation of amyloid-like proteins underlies the pathologies of Alzheimer's and Senexis has discovered potent and selective compounds that protect cells and tissues from the toxic forms of amyloid. Further information on Senexis can be found at www.senexis.com.

About Tallphil Productions

Tallphil Productions is the production name for graphic and web design by Phil Ewels. Having produced websites for close to 10 years, I have gained significant experience and have recently been involved in a number of websites for the scientific community. You can find out more information at www.tallphilproductions.co.uk

